Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Female gamete preservation.

Victoria J Davis1

  • 1Department of Obstetrics and Gynecology, University of Toronto, Hospital for Sick Children, Toronto, Ontario, Canada. vdavis@organon.ca

Cancer
|August 12, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rare cause of vaginal bleeding in early puberty.

Journal of pediatric and adolescent gynecology·2005
Same author

A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon) in women undergoing controlled ovarian hyperstimulation for IVF treatment.

Journal of assisted reproduction and genetics·2005
See all related articles

Cancer therapies like chemotherapy and radiation can harm ovaries, impacting fertility in young survivors. Assisted reproductive technologies offer potential solutions, but their effectiveness requires further research and patient counseling.

Area of Science:

  • Reproductive medicine
  • Oncology
  • Pediatric oncology

Background:

  • Cancer survival rates for children and adolescents have significantly improved due to advancements in chemotherapy and combined modality treatments.
  • Long-term consequences of these cancer therapies, particularly on reproductive health, are a growing concern for survivors transitioning into adulthood.
  • Ovarian damage, including follicle depletion, is a significant risk associated with gonadotoxic treatments like alkylating agents and radiation therapy.

Purpose of the Study:

  • To review the impact of cancer therapies on ovarian function in young survivors.
  • To explore the potential of assisted reproductive technologies (ART) in mitigating the reproductive sequelae of cancer treatment.
  • To highlight the importance of informed decision-making regarding fertility preservation options.

Related Experiment Videos

Main Methods:

  • Review of current literature on the gonadotoxicity of cancer treatments.
  • Analysis of established and emerging assisted reproductive technologies (ART) for fertility preservation.
  • Discussion of pre-treatment and post-treatment reproductive strategies.

Main Results:

  • Chemotherapy and radiation significantly increase the risk of impaired gonadal function and infertility in young cancer survivors.
  • While ART offers promising avenues, including embryo/gamete cryopreservation and donor options, their success rates and applicability vary.
  • Ovarian protection methods like oral contraceptives and GnRH agonists have not demonstrated proven benefits, and oocyte/ovary cryopreservation has limited success.

Conclusions:

  • Young cancer survivors face a substantial risk of infertility due to cancer treatments.
  • Assisted reproductive technologies (ART) and fertility preservation strategies are crucial for addressing the reproductive concerns of these patients.
  • Comprehensive counseling on potential fertility effects and available options is essential for informed decision-making by patients and their families.